Glioblastoma Foundation is ranked among medical research organizations in Durham, NC, with an America's Best Score of 80 out of 100, based on its 2024 Form 990.
Among the 6 scored medical research organizations in Durham, Glioblastoma Foundation holds 20.7 months of operating reserves (peer median 21.6 months), runs a typical yearly surplus of 46.4% (peers: surplus of 1.4%), and has grown spending 37.6% a year (peers: grown spending 29.0% a year).
In fiscal year 2024 it reported $2,055,218 in revenue and $1,833,664 in expenses, with contributions making up 95.6% of revenue.
The Glioblastoma Foundation is dedicated to finding a cure for glioblastoma by funding research and drug development, supporting patients and families, and raising national awareness of this devastating brain cancer. Through these integrated programs, the foundation accelerates scientific discovery, empowers patients with information and resources, and educates the public about the urgent need for better treatments and improved outcomes.
Largest programs · fiscal year 2024
Research and drug development:in 2024, the Glioblastoma Foundation advanced its research mission by acquiring lisavanbulin, a promising targeted therapy from basilea pharmaceutica, for further clinical development in glioblastoma. This acquisition marked a critical step toward bringing patients new, more effective treatments. The foundation also supported investigator-initiated research on molecul… Read more
Research and drug development:in 2024, the Glioblastoma Foundation advanced its research mission by acquiring lisavanbulin, a promising targeted therapy from basilea pharmaceutica, for further clinical development in glioblastoma. This acquisition marked a critical step toward bringing patients new, more effective treatments. The foundation also supported investigator-initiated research on molecular characterization and functional precision oncology. Additionally, the foundation established gliolab, a clia-registered genomic laboratory that will provide state-of-the-art testing to accelerate discovery of targeted therapies based on each tumor's genomic and epigenomic profile.
$527,251 spent · 33.3% of program spending
Patient support and education:throughout 2024, the foundation provided support services for glioblastoma patients and caregivers nationwide, including personalized clinical-trial matching, professionally led virtual support groups, and educational resources on treatment options and emerging research. These programs empowered patients to make informed care decisions and fostered a sense of communit… Read more
Patient support and education:throughout 2024, the foundation provided support services for glioblastoma patients and caregivers nationwide, including personalized clinical-trial matching, professionally led virtual support groups, and educational resources on treatment options and emerging research. These programs empowered patients to make informed care decisions and fostered a sense of community among families affected by this rare disease. Hundreds of patients and caregivers benefited from these free services during the year.
$527,251 spent · 33.3% of program spending
Public awareness and advocacy:the foundation led nationwide efforts to raise awareness and advocacy for those affected by glioblastoma. In 2024, it organized glioblastoma awareness day and continued the voices of glioblastoma podcast while planning to expand the series in future years to feature additional patient, caregiver, and scientist perspectives. The foundation also partnered with events su… Read more
Public awareness and advocacy:the foundation led nationwide efforts to raise awareness and advocacy for those affected by glioblastoma. In 2024, it organized glioblastoma awareness day and continued the voices of glioblastoma podcast while planning to expand the series in future years to feature additional patient, caregiver, and scientist perspectives. The foundation also partnered with events such as the los angeles marathon to increase public understanding and support for research. These initiatives educated thousands and inspired hope within the glioblastoma community.
$527,250 spent · 33.3% of program spending
Where each dollar went · fiscal year 2024
Of every dollar it spent, 86¢ went to programs, 13¢ to management and 1¢ to fundraising.
Programs $1,581,752
Management $237,982
Fundraising $13,930
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
86%
Meets
Compared with Durham peers
Measure
This organization
Peer median
Operating reserves
20.7 mo
21.6 mo
Typical margin
+46.4%
+1.4%
Spending growth
+37.6% / yr
+29.0% / yr
Debt load
13.6%
9.0%
Peers: the 6 Durham medical research organizations with a score, ranked or below the bar.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$2,055,218Fiscal year 2024
Expenses$1,833,664Fiscal year 2024
Total assets$3,662,658Fiscal year 2024
Total liabilities$496,171Fiscal year 2024
Fiscal year ending December2024
Revenue$2,055,218
Expenses$1,833,664
Net income$221,554
Net assets$3,166,487
Notable sources of revenue
Percent of total revenue
Contributions
$1,964,537
95.6%
Program services
$0
0.0%
Investment income
$2,803
0.1%
Other (net)
$87,878
4.3%
Assets / debt
Total assets
$3,662,658
Total liabilities
$496,171
Net assets
$3,166,487
Compensation
Not in our extract for this year.
Fiscal year ending December2023
Revenue$1,699,784
Expenses$1,411,492
Net income$288,292
Net assets$2,482,026
Notable sources of revenue
Percent of total revenue
Contributions
$1,691,690
99.5%
Program services
$0
0.0%
Investment income
$8,094
0.5%
Other (net)
$0
0.0%
Assets / debt
Total assets
$2,482,026
Total liabilities
$0
Net assets
$2,482,026
Compensation
Not in our extract for this year.
Fiscal year ending December2022
Revenue$1,471,550
Expenses$853,578
Net income$617,972
Net assets$1,781,399
Notable sources of revenue
Percent of total revenue
Contributions
$1,513,382
102.8%
Program services
$0
0.0%
Investment income
$14,333
1.0%
Other (net)
−$56,165
−3.8%
Assets / debt
Total assets
$1,781,399
Total liabilities
$0
Net assets
$1,781,399
Compensation
Officers and key employees
$192,826
Share of expenses
22.6%
Fiscal year ending December2021
Revenue$1,253,574
Expenses$703,351
Net income$550,223
Net assets$1,523,936
Notable sources of revenue
Percent of total revenue
Contributions
$1,302,093
103.9%
Program services
$0
0.0%
Investment income
$9,185
0.7%
Other (net)
−$57,704
−4.6%
Assets / debt
Total assets
$1,523,936
Total liabilities
$0
Net assets
$1,523,936
Compensation
Officers and key employees
$180,000
Share of expenses
25.6%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?